(6-Chloropyridin-3-yl)methyl 1-((6-chloropyridin-3-yl)methyl)piperidine-2-carboxylate

Catalog No. :
ACDEND982
CAS No. :
1261229-58-6
Molecular Formula :
C18H19Cl2N3O2
Molecular Weight :
380.27

IUPAC Name:(6-chloropyridin-3-yl)methyl 1-((6-chloropyridin-3-yl)methyl)piperidine-2-carboxylate

(6-Chloropyridin-3-yl)methyl 1-((6-chloropyridin-3-yl)methyl)piperidine-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$595.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(6-Chloropyridin-3-yl)methyl 1-((6-chloropyridin-3-yl)methyl)piperidine-2-carboxylate
IUPAC Name(6-chloropyridin-3-yl)methyl 1-((6-chloropyridin-3-yl)methyl)piperidine-2-carboxylate
MDL No.MFCD18380339
Molecular FormulaC18H19Cl2N3O2
Molecular Weight380.27
SMILESO=C(C1N(CC2=CC=C(Cl)N=C2)CCCC1)OCC3=CC=C(Cl)N=C3
InChI KeyPUKAFVDAHGVGOK-UHFFFAOYSA-N
Synonym1-(6-Chloro-pyridin-3-ylMethyl)-piperidine-2-carboxylic acid 6-chloro-pyridine -3-ylMethyl ester
CAS No.1261229-58-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACDEND982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNMKF357 route compound structure diagram
    ACNMKF35721543-49-7 In Stock
  4. Then
  5. ACDEND982 route product structure diagram
    ACDEND9821261229-58-6
Inquiry

2. ACDEND982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDEND982 route product structure diagram
    ACDEND9821261229-58-6
Inquiry

Comments (0)